Fluxion, Swift jointly develop NGS workflow, 9/15

Fluxion Biosciences and Swift Biosciences announced a jointly developed workflow for oncology clinical research designed to detect somatic mutations from a routine blood draw. The workflow uses Fluxion’s IsoFlux System for circulating tumor cell enrichment and Swift’s Accel-Amplicon technology for high-sensitivity variant detection using low starting inputs.

The IsoFlux System enriches rare tumor cells circulating in the blood using a combination of epithelial and mesenchymal markers and delivers them at high purity for molecular analysis. Swift’s Accel-Amplicon 56G Oncology Panel provides sensitive mutation detection across 56 cancer-related genes using very low starting DNA inputs from the IsoFlux System, making this combination of technologies appropriate for liquid biopsy samples.

Swift Biosciences, 734-330-2568

Fluxion Biosciences, 650-241-4777